Category Archives: adherence

  1. VOICE Lesson: It’s Unfair to be Non-Adherent

    This post by IRMA’s Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance. The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out Read More >>

    adherence, Africa, hiv prevention, HIV Prevention Justice Alliance, HIV/AIDS policy, new prevention technologies, pre-exposure prophylaxis, PrEP, research, Tenofovir, Truvada, vaginal microbicide, VOICE
  2. PrEP: time to rethink prevention, effectiveness and ethics?

    via Somatosphere, by Marsha Rosengarten One of the more controversial interventions proposed for HIV prevention in those who test HIV antibody negative and perceived to be at risk is pre-exposure prophylaxis (PrEP) – a daily pill comprising one or two antiretroviral drugs manufactured by Gilead Inc. Besides the mixed results from multi-site randomised controlled trials (RCTs) seeking Read More >>

    adherence, Bill and Melinda Gates Foundation, FEM-PrEP, Gilead, hiv prevention, iPrEx, pre-exposure prophylaxis, PrEP, Treatment as Prevention
  3. Kenya: Counselling, not alarm device, had best effect on ART adherence

    Via aidsmap, by Carole Leach-Lemens Patients in Nairobi, Kenya getting intensive early adherence counselling when starting antiretroviral therapy were 29% less likely to have poor adherence and 59% less likely to have virological failure compared to those getting no counselling Michael H Chung and colleagues reported in a randomised, controlled trial published in the March issue of Read More >>

    adherence, antiretroviral therapy, ART, counseling, HIV/AIDS, Kenya, public health, resistance, sub-saharan Africa, Treatment
  4. Toward an Information-Motivation-Behavioral Skills Model of Microbicide Adherence in Clinical rials

    Via AIDS Care, Rebecca A. Ferrerab; Kathleen M. Morrowcd; William A. Fishere; Jeffrey D. Fisherbf Unless optimal adherence in microbicide clinical trials is ensured, an efficacious microbicide may be rejected after trial completion, or development of a promising microbicide may be stopped, because low adherence rates create the illusion of poor efficacy. We provide a framework with Read More >>

    adherence, clinical trials, vaginal microbicide